<DOC>
	<DOCNO>NCT00903383</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , effectiveness LX3305 versus placebo control subject active rheumatoid arthritis stable methotrexate therapy .</brief_summary>
	<brief_title>Study LX3305 Subjects With Active Rheumatoid Arthritis Stable Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Males female age 1875 year old Rheumatoid arthritis present least 6 month , functional class I , II , III define ACR criterion Active disease determine presence ≥6 swollen joint , ≥6 tender joint , serum Creactive protein level &gt; upper limit normal Receiving stable dose MTX ( ≥10 mg/wk ) folate supplementation least 8 week prior Day 1 Ability provide write informed consent RA diagnosis prior 16 year age ( Juvenile RA ) Lack response &gt; 3 disease modify antirheumatic drug ( DMARDs ) exposure &gt; 1 biologic DMARD Use DMARDs MTX within 12 week prior Day 1 Intraarticular and/or parenteral corticosteroid within 4 week prior study Day 1 Blood donation receipt live vaccine within 4 week prior Day 1 Major surgical procedure within 8 week prior Day 1 Any systemic inflammatory condition , recurrent infection , current infection onychomycosis History cancer within 5 year prior Day 1 Presence hepatic biliary disease History tuberculosis History human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>